参考文献
1: Khodor S, Castro M, McNamara C, Chaulagain CP. Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab. Hematol Oncol Stem Cell Ther. 2015 Dec 2. pii: S1658-3876(15)00105-3. doi: 10.1016/j.hemonc.2015.11.003. [Epub ahead of print] PubMed PMID: 26684918.
2: Zhang JR, Wang DQ, Du J, Qu GS, Du JL, Deng SB, Liu YJ, Cai JX, She Q. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore). 2015 Dec;94(50):e2262. doi: 10.1097/MD.0000000000002262. PubMed PMID: 26683949.
3: Yang YG, Zhang M, Jiang N, Song LX, Xu XT, Di XH, Xu L, Xu J, Zhao GT. Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. Genet Mol Res. 2015 Dec 14;14(4):16736-43. doi: 10.4238/2015.December14.1. PubMed PMID: 26681020.
4: Ketterer U, D Ancona G, Siegel I, Ortak J, Ince H, Kische S. Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders. Int J Cardiol. 2015 Nov 24;204:196-197. doi: 10.1016/j.ijcard.2015.11.160. [Epub ahead of print] PubMed PMID: 26670171.
5: Zhai Y, Wang L, Yang F, Feng G, Feng S, Cui T, An L, He X. The mechanism and risk factors of clopidogrel-induced liver injury. Drug Chem Toxicol. 2015 Dec 11:1-8. [Epub ahead of print] PubMed PMID: 26654298.
6: Nishimura AA, Shirts BH, Salama J, Smith JW, Devine B, Tarczy-Hornoch P. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2015 Nov 11. pii: S1386-5056(15)30056-3. doi: 10.1016/j.ijmedinf.2015.11.004. [Epub ahead of print] PubMed PMID: 26642939.
7: Dobesh PP, Varnado S, Doyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. Curr Pharm Des. 2015 Dec 8. [Epub ahead of print] PubMed PMID: 26642781.
8: Braun D, Knipper A, Orban M, Sibbing D, Petzold T, Braun S, Schulz S, Hausleiter J, Kastrati A, Mehilli J, Massberg S. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thromb Res. 2015 Nov 19. pii: S0049-3848(15)30192-4. doi: 10.1016/j.thromres.2015.11.016. [Epub ahead of print] PubMed PMID: 26639204.
9: Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2015 Dec 5. pii: ehv611. [Epub ahead of print] PubMed PMID: 26637834.
10: Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni M, Guzman LA, Bass TA, Ajjan RA, Angiolillo DJ. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost. 2015 Dec 3;115(3). [Epub ahead of print] PubMed PMID: 26633836.
